A Phase I Study of the NovoTTF-200M and Novo TTF-200A Systems for the Treatment of Refractory Spinal Metastasis

Recruiting

Phase 1

NovoTTF-200M & NovoTTF-200AA Phase I Study of the NovoTTF-200M and Novo TTF-200A Systems for the Treatment of Refractory Spinal Metastasis

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT06906900

Conditions

Spinal Metastasis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

TTF-200M and TTF-200A systems

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-03. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2025-10-24.